BIOM'UP BUY | Fair Value EUR16.5 Reiterating positive stance following analysts’ call with CEO
BIOM'UP BUY | Fair Value EUR16.5 Reiterating positive stance following analysts’ call with CEOWe return to the analysts’ call held on Tuesday by Biom’up’ CEO and reiterate our positive stance on the company’s ongoing execution plan, which aims at maximizing the adoption of HEMOBLAST Bellows among surgeons. Strong focus of the expanded commercial team on leading hospitals bodes well for supply agreements/orders in H2 2018.
Share-based compensationBiom'Up develops and sells collagen-based implantable and resorbable medical and biomaterial devices derived from biopolymers mainly in France and the United States. Co. has created clinically tested products for use in many specialties such as orthopedic, spinal, acrothoracic, general, maxillofacial and dental surgeries. Co.'s portfolio includes the following products: MATRI™ BONE and COVA™, trademarked in 2009, HEMOSNOW™ in 2012, COVAMESH™ in 2013 and Co.'s flagship product HEMOBLAST™ Bellows trademarked in 2016. In the United States, Co. obtained Pre-Market Approval (PMA) for HEMOBLAST™ Bellows, giving it access to the North American market.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.